Metformin Stada

Metformin Hydrochloride, the active ingredient in Metformin Stada, is a biguanide presented as a oral tablet for oral use. It treats type 2 diabetes mellitus in adults. GNH USA supplies Metformin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Stada is used to manage hyperglycaemia in the type 2 diabetes pathway. - Type 2 diabetes mellitus: improves glycaemic control and lowers HbA1c. - Adjunct to diet and exercise: helps achieve target fasting and post‑prandial glucose levels. - Combination therapy: can be added to other antidiabetic agents to reach individualized glucose goals.

Metformin Stada may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhoea: loose stools, often transient. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration of taste. - Weight loss: modest reduction in body weight. - Vitamin B12 deficiency: decreased absorption with long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic acidosis. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatotoxicity: elevated liver enzymes. - Hypoglycaemia: when combined with insulin or sulfonylureas. - Acute pancreatitis: very uncommon. - Anaphylactic reaction: rare hypersensitivity.

Metformin Stada requires careful monitoring and patient education. - Renal function: assess creatinine clearance before initiation and periodically thereafter. - Hepatic function: avoid use in patients with significant liver disease. - Contraindication: do not use in severe renal impairment (eGFR <30 mL/min/1.73 m²). - Alcohol consumption: limit intake to reduce risk of lactic acidosis. - Elderly patients: start at lower doses and monitor for accumulation. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Metformin Stada can interact with several medicines, requiring dose adjustment or monitoring.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations. - Alcohol: potentiates lactic acidosis. - Nucleoside reverse transcriptase inhibitors: may increase metformin levels.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - Diuretics: can affect renal clearance of metformin. - ACE inhibitors/ARBs: monitor renal function and potassium. - Warfarin: occasional alteration of INR, require monitoring. - Digoxin: watch for changes in serum levels.